Latest Intelligence on Central Nervous System

Published within

« | ... | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Shire/GSK: co-promotion deal too late for Vyvanse

Shire has announced a deal with GlaxoSmithKline to co-promote the ADHD treatment Vyvanse in the US. Shire's successful marketing of the leading blockbuster brand, Adderall XR, in the absence of such a partner may indicate that GlaxoSmithKline's contribution will be both marginal and too late, coming as it does after the launch of generic versions of Adderall XR.

Published By Datamonitor
01 Apr 2009
CommentWire
CommentWire

Shire/Barr: excitement levels rise on Adderall deal

Shire Pharmaceuticals has settled a crucial patent case with US generics company Barr Laboratories regarding its ADHD drug Adderall XR. The agreement will prove vital to Shire, minimizing the generic threat and giving the company time to move patients over to its late-stage pipeline ADHD drug, NRP 104, should it gain approval.

Published By Datamonitor
16 Aug 2006
CommentWire
CommentWire

Shire Pharmaceuticals: promising pipeline

The FDA approval of ulcerative colitis drug Lialda is positive news for a trio of companies: Shire, Giuliani and Cosmo SpA. Lialda's minimum once daily dosage regime is a significant step forward for ulcerative colitis treatment which should lead to strong sales in the indication, with some additional revenue generated from off-label sales for the treatment of other lower GI tract conditions.

Published By Datamonitor
19 Jan 2007
CommentWire
CommentWire

Shire Pharmaceuticals: astute move for New River

The main driver of this Shire's plan to acquire New River is Vyvanse, New River Pharmaceutical's new ADHD drug and potential follow up to Shire's Adderall XR, which is estimated to expire in 2009. If Vyvanse can live up to its potential, the deal will ensure that Shire maintains its market leading position in the ADHD treatment sector.

Published By Datamonitor
21 Feb 2007
CommentWire
CommentWire

Shire / Noven: patching up ADHD

Following trials of their methylphenidate transdermal system (MTS), which is in development for the treatment of attention deficit hyperactivity disorder (ADHD) in children, Noven and Shire have announced positive preliminary results. The drug should launch in the US by the end of 2006, and has the potential to become the market leading ADHD stimulant by 2010.

Published By Datamonitor
07 Apr 2005
CommentWire
CommentWire

Servier/Novartis: potential blockbuster Valdoxan is set to lead the market

Pooled analysis of four major studies of Valdoxan has shown significantly greater efficacy and an increased percentage of responders than conventional depression treatments. Due to its novel mechanism of action, strong efficacy profile, increased tolerability and potential to alleviate comorbid sleep disturbances, Valdoxan is well positioned to become a leading treatment in the depression market.

Published By Datamonitor
03 Sep 2010
CommentWire
CommentWire

Serono: the future is bright with Rebif

The regulator's decision to break the orphan drug status of Biogen's Avonex and allow Rebif's US sale is a massive boost to Serono's growth prospects. The resulting extra revenues should allow Serono to increase its comparatively weak pipeline through in-licensing deals - and also by going on the acquisition trail.

Published By Datamonitor
13 Mar 2002
CommentWire
CommentWire

Serono: reliance on Rebif

Strong sales for multiple sclerosis drug Rebif have failed to prevent a fall in Q3 profits for Swiss biotech firm Serono. Having already been hit by settlement charges related to its HIV treatment Serostim earlier this year, and given the company's relatively weak pipeline, it is now crucial that Serono looks to the effective use of its financial resources in order to ensure a profitable future.

Published By Datamonitor
26 Oct 2005
CommentWire
CommentWire

Serono: Parkinson's drug deal will fit with Merck merger

The addition of safinamide to Serono's late stage R&D pipeline will fill the gap left by Merck KGaA's halted Parkinson's disease (PD) product, sarizotan, when the two companies merge to form Merck-Serono Biopharmaceuticals. However, the drug is not expected to have a large impact on the PD market and thus will not be a key growth driver for the company.

Published By Datamonitor
18 Oct 2006
CommentWire
CommentWire

Serono: new Rebif formulation shows promise

Serono has announced data from an ongoing two year Phase IIIb trial demonstrating that the new formulation of multiple sclerosis drug Rebif offers improvement in tolerability and immunogenicity profiles. Although, if launched, the drug is expected to lead to improved compliance, long term uptake will be threatened by the development of oral formulation drugs.

Published By Datamonitor
29 Sep 2006

« | ... | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | ... | » »|

No help is available.